Executive record
Ryan J. Selhorn
Public governance roles and source-backed Claims for this individual.
More
Alpha ID: alpha:person:ryan-j-selhornVersion: public-0As of: 2026-10-01
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Served as Executive Vice President, Finance and Business Optimization since November 2022 and previously as Senior Vice President, Finance and Operations. Served as Vice President and Chief Financial Officer at Innovus Pharmaceuticals, Inc. from April 2018 until Aytu's acquisition in February 2020. Worked at Grant Thornton LLP as Senior Manager, Transaction Advisory Services.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Board service coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageExecutive career
- 2025 to end not publishedExecutive title: Chief Financial Officer, Corporate Secretary, and Treasurer · Organization not publishedAYTU DEF 14A executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
AYTU DEF 14A executive officers
sec filing · Source published: Oct 24, 2025 · Retrieved: May 15, 2026
Supports 5 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Executive company: Executive at AYTU BIOPHARMA, INC · Claim reviewed: May 15, 2026
- Executive title: Executive title: Chief Financial Officer, Corporate Secretary, and Treasurer · Claim reviewed: May 15, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01
- Biography
- published
- Board service
- not observed
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope

